Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$18.05 CAD
Change Today +0.015 / 0.08%
Volume 110.3K
GDI On Other Exchanges
Symbol
Exchange
GDI is not on other exchanges.
As of 3:59 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

6030-88 Street

Edmonton, AB T6E 6G4

Canada

Phone: 780-413-7152

Fax: 780-408-3040

BioMS Medical Corp., a biotech company, engages in the development and commercialization of therapeutic technologies with emphasis on the treatment of Multiple Sclerosis (MS). The company has three subsidiaries, BioMS Technology Corp. (BioMS Tech), BioMS Technology U.S. Corp. and BioMS Technology International Limited. The company has obtained a worldwide license to a proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The technology, dirucotide (formally named MBP8298), is a synthetic myelin basic protein peptide comprised of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment. The company is conducting late-stage clinical trials and one open-label trial for dirucotide in secondary progressive MS. The company focuses on advancing the clinical development of its product Dirucotide for the treatment of multiple sclerosis. It is in the process of conducting four clinical trials with Dirucotide. The MAESTRO-01 trial is, a pivotal Phase II/III, multi-centre, double blind, placebo-controlled trial designed to evaluate the safety and efficacy of Dirucotide in patients with secondary progressive multiple sclerosis (SPMS). HYC750 BioMS Tech held a worldwide license to technology from the University of Alberta, which involves a method for mobilizing hematopoetic cells in humans. History BioMS Medical Corp. was founded in 1998. The company was formerly known as EPS Capital Corp. and changed its name to BioMS Medical Corp. in 2001.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GDI:CN C$18.05 CAD +0.015

GDI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GDI.
View Industry Companies
 

Industry Analysis

GDI

Industry Average

Valuation GDI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GDI INTEGRATED FACILITY SERV, please visit www.medwellcapital.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.